Tandem Diabetes Care, Inc. announced that its Development and Commercialization Agreement with DexCom, Inc. has been expanded to include Dexcom's newest continuous glucose monitoring system, the G4(TM) PLATINUM. Dexcom announced in October that the G4 PLATINUM was approved by the U.S. Food and Drug Administration (FDA). According to clinical trials conducted by Dexcom, the G4 PLATINUM has improved overall accuracy and ease of use compared to the company's previous Seven Plus CGM.

The Development and Commercialization Agreement between Tandem and Dexcom is non-exclusive and limited to the U.S. market.